PURPOSE: Mastectomy has long been the preferred approach for local salvage of recurrent breast cancer following breast-conservation therapy (BCT). Growing interest in avoiding mastectomy prompted RTOG 1014, a landmark phase two study demonstrating the feasibility of repeat BCT using a novel radiotherapy (RT) regimen (i.e., 45 Gy administered in 30 fractions of 1.5 Gy twice-daily to the partial breast, "rePBI"). We adopted this regimen as our institutional standard and report our observations regarding the safety and efficacy of rePBI as salvage therapy. METHODS: All patients at our institution who underwent repeat BCT and subsequently received rePBI from 2011 to 2019 were identified. Clinicopathologic features and treatment characteristics for both primary breast cancers and recurrences were collected, as were rates of subsequent recurrence and treatment-associated toxicities. RESULTS: The cohort included 34 patients with a median age of 65.8 (46.2-78.2) at the time of rePBI. At a median follow-up of 23.5 months, there were two subsequent locoregional recurrences (2-year local control rate 97%). There was no grade ≥ 3 toxicity. The most common acute toxicity (< 3 months) was radiation dermatitis (100%), and common grade 1-2 late toxicities (> 3 months) included fibrosis in 14 (41%), breast asymmetry in 12 (35%), and chest wall pain in 11 (32%). CONCLUSIONS: Repeat breast conservation using the hyperfractionated partial breast RT regimen defined by RTOG 1014 (45 Gy administered in 30 1.5 Gy twice-daily fractions) appears effective and well tolerated. No grade 3 or higher toxicities were observed and local control was excellent. Longer term follow-up among larger cohorts will define whether salvage mastectomy should remain the preferred standard.
PURPOSE: Mastectomy has long been the preferred approach for local salvage of recurrent breast cancer following breast-conservation therapy (BCT). Growing interest in avoiding mastectomy prompted RTOG 1014, a landmark phase two study demonstrating the feasibility of repeat BCT using a novel radiotherapy (RT) regimen (i.e., 45 Gy administered in 30 fractions of 1.5 Gy twice-daily to the partial breast, "rePBI"). We adopted this regimen as our institutional standard and report our observations regarding the safety and efficacy of rePBI as salvage therapy. METHODS: All patients at our institution who underwent repeat BCT and subsequently received rePBI from 2011 to 2019 were identified. Clinicopathologic features and treatment characteristics for both primary breast cancers and recurrences were collected, as were rates of subsequent recurrence and treatment-associated toxicities. RESULTS: The cohort included 34 patients with a median age of 65.8 (46.2-78.2) at the time of rePBI. At a median follow-up of 23.5 months, there were two subsequent locoregional recurrences (2-year local control rate 97%). There was no grade ≥ 3 toxicity. The most common acute toxicity (< 3 months) was radiation dermatitis (100%), and common grade 1-2 late toxicities (> 3 months) included fibrosis in 14 (41%), breast asymmetry in 12 (35%), and chest wall pain in 11 (32%). CONCLUSIONS: Repeat breast conservation using the hyperfractionated partial breast RT regimen defined by RTOG 1014 (45 Gy administered in 30 1.5 Gy twice-daily fractions) appears effective and well tolerated. No grade 3 or higher toxicities were observed and local control was excellent. Longer term follow-up among larger cohorts will define whether salvage mastectomy should remain the preferred standard.
Entities:
Keywords:
Breast cancer; Breast conservation; Local recurrence; Local therapy; Radiotherapy; Salvage
Authors: B Salvadori; E Marubini; R Miceli; A R Conti; F Cusumano; S Andreola; R Zucali; U Veronesi Journal: Br J Surg Date: 1999-01 Impact factor: 6.939
Authors: G van Tienhoven; A C Voogd; J L Peterse; M Nielsen; K W Andersen; F Mignolet; R Sylvester; I S Fentiman; E van der Schueren; K van Zijl; M Blichert-Toft; H Bartelink; J A van Dongen Journal: Eur J Cancer Date: 1999-01 Impact factor: 9.162
Authors: Frank A Vicini; Reena S Cecchini; Julia R White; Douglas W Arthur; Thomas B Julian; Rachel A Rabinovitch; Robert R Kuske; Patricia A Ganz; David S Parda; Michael F Scheier; Kathryn A Winter; Soonmyung Paik; Henry M Kuerer; Laura A Vallow; Lori J Pierce; Eleftherios P Mamounas; Beryl McCormick; Joseph P Costantino; Harry D Bear; Isabelle Germain; Gregory Gustafson; Linda Grossheim; Ivy A Petersen; Richard S Hudes; Walter J Curran; John L Bryant; Norman Wolmark Journal: Lancet Date: 2019-12-05 Impact factor: 79.321
Authors: Timothy J Whelan; Jim A Julian; Tanya S Berrang; Do-Hoon Kim; Isabelle Germain; Alan M Nichol; Mohamed Akra; Sophie Lavertu; Francois Germain; Anthony Fyles; Theresa Trotter; Francisco E Perera; Susan Balkwill; Susan Chafe; Thomas McGowan; Thierry Muanza; Wayne A Beckham; Boon H Chua; Chu Shu Gu; Mark N Levine; Ivo A Olivotto Journal: Lancet Date: 2019-12-05 Impact factor: 79.321
Authors: Douglas W Arthur; Kathryn A Winter; Henry M Kuerer; Bruce G Haffty; Laurie W Cuttino; Dorin A Todor; Nicole L Simone; Shelly B Hayes; Wendy A Woodward; Beryl McCormick; Randi J Cohen; Walter M Sahijdak; Daniel J Canaday; Doris R Brown; Adam D Currey; Christine M Fisher; Reshma Jagsi; Julia White Journal: Int J Radiat Oncol Biol Phys Date: 2017-03-18 Impact factor: 7.038
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Indrani S Bhattacharya; Joanne S Haviland; Anna M Kirby; Cliona C Kirwan; Penelope Hopwood; John R Yarnold; Judith M Bliss; Charlotte E Coles Journal: J Clin Oncol Date: 2018-12-11 Impact factor: 44.544
Authors: Astrid Botty Van den Bruele; Ishita Chen; Varadan Sevilimedu; Tiana Le; Monica Morrow; Lior Z Braunstein; Hiram S Cody Journal: Breast Cancer Res Treat Date: 2021-01-12 Impact factor: 4.872